Jessica Serra | Head, IR & and ESG |
Mark Foley | CEO |
Dustin Sjuts | President |
Toby Schilke | CFO |
Ken Cacciatore | Cowen and Company |
Alena Seamus Fernandez | Guggenheim |
David Amsellem | Piper Sandler |
Annabel Samimy | Stifel |
Balaji Prasad | Barclays |
Tim Lugo | William Blair |
Douglas Tsao | H.C. Wainwright |
Serge Belanger | Needham & Company |
0:04 Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following management’s prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we will ask for a limit of one question and one follow up question per person. [Operator Instructions].